Email Us Here

First Heart Attack Patient Treated in European Cardioprotection Phase III Trial with NeuroVive's CicloMulsion (TM)

Investigator-initiated European multicenter trial of 1,000 acute heart attack patients will examine the ability of cyclosporine to protect cardiac tissue.